Management of T2DM in 2017

Clinically relevant results from cardiovascular outcome trials

The risk of death from cardiovascular causes in people with type 2 diabetes mellitus remains around twice that in the general population, with heart failure a common event. In 2017, results from cardiovascular outcome trials in people with diabetes mellitus showed that some drugs have dual utility — reducing cardiovascular risk and improving glycaemic control.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1

    McMurray, J. J. et al. Heart failure: a cardiovascular outcome in diabetes that can no longer be ignored. Lancet Diabetes Endocrinol. 2, 843–851 (2014).

    CAS  Article  Google Scholar 

  2. 2

    Neal, B. et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644–657 (2017).

    CAS  Article  Google Scholar 

  3. 3

    Birkeland, K. I. et al. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis. Lancet Diabetes Endocrinol. 5, 709–717 (2017).

    CAS  Article  Google Scholar 

  4. 4

    McMurray, J. J. et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 371, 993–1004 (2014).

    Article  Google Scholar 

  5. 5

    Seferovic, J. P. et al. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 5, 333–340 (2017).

    CAS  Article  Google Scholar 

  6. 6

    Ridker, P. M. et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377, 1119–1131 (2017).

    CAS  Article  Google Scholar 

  7. 7

    Ridker, P. M. et al. Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390, 1833–1842 (2017).

    CAS  Article  Google Scholar 

  8. 8

    Holman, R. R. et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance: a randomised controlled trial. Lancet Diabetes Endocrinol. 5, 877–886 (2017).

    CAS  Article  Google Scholar 

  9. 9

    Li, G. et al. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2, 474–480 (2014).

    Article  Google Scholar 

  10. 10

    Xu, Y. et al. Prevalence and control of diabetes in Chinese adults. JAMA 310, 948–959 (2013).

    CAS  Article  Google Scholar 

Download references


The author is an National Institute for Health Research senior investigator.

Author information



Corresponding author

Correspondence to Rury R. Holman.

Ethics declarations

Competing interests

R.R.H. has received grants and personal fees from Bayer AG relating to the ACE study and personal fees from Novartis.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Holman, R. Clinically relevant results from cardiovascular outcome trials. Nat Rev Endocrinol 14, 67–68 (2018).

Download citation

Further reading


Quick links

Sign up for the Nature Briefing newsletter for a daily update on COVID-19 science.
Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing